Sugi Predict

Sugi Predict / Compounds / Morocromen

Morocromen

Morocromen

SCHEMBL2109013

Cc1c(CCN2CCOCC2)c(=O)oc2cc(NC(=O)N3CCOCC3)ccc12

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.57
▸ KDM4E B2RXH2 6/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ RAB9A P51151 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ TP53 P04637 1/20 0.57
▸ MEN1 O00255 5/20 0.52
▸ KMT2A Q03164 5/20 0.52
▸ HPGD P15428 4/20 0.50
▸ HSD17B10 Q99714 4/20 0.50
▸ GAA P10253 4/20 0.50
▸ GLA P06280 2/20 0.49
▸ CASP1 P29466 2/20 0.49
▸ CASP7 P55210 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ THRB P10828 1/20 0.46
▸ ALOX15 P16050 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11476163 0.85 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL7602694 0.78 HRH3 (0.58) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL11477896 0.76 TSHR (0.48) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1
Cinecromen SCHEMBL11484776 0.73 CA12 (0.46) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1
Cinecromen SCHEMBL2111176 0.73 CA12 (0.46) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL11479709 0.72 MAPT (0.47) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1
SCHEMBL7598173 0.72 HRH3 (0.61) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1942780 0.69 MEN1 (0.63) ALDH1A1KDM4ERAB9ANPC1MEN1
SCHEMBL7601498 0.68 HRH3 (0.64) —
SCHEMBL5852053 0.68 GAA (0.73) ALDH1A1KDM4ESMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 — — US disclosed
EP-2717860-A1 CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION STI Pharma, LLC (US) 2014-04-16 — — EP disclosed
US-8454582-B2 Methods and devices for the treatment of ocular conditions SURMODICS, INC. (US) 2013-06-04 — — US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed
US-4241207-A CORONARY DILATORS TROPONWERKE DINKLAGE & CO. (DE) 1980-12-23 — — US disclosed
US-4144336-A 2-Benzopyranone derivatives, process for their production, their use as medicaments, more especially as coronary dilators TROPONWERKE DINKLAGE & CO. (DE) 1979-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 ALDH1A1 4459/4885KDM4E 4426/4885SMN1; SMN2 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.